9 signals this week: 4 Quality, 1 Clinical trials, 4 Regulatory

NIAC and JCVI will need to evaluate mFlusiva once FDA rules by 5 August, since a positive US approval puts an mRNA option in front of national immunisation committees that have only ever assessed egg- or cell-based flu vaccines for routine seasonal use.

BLA licensure under 21 USC 351; accelerated-approval pathway under 21 CFR 601.41-44 applies to the 65+ population and carries a Phase IV confirmatory-trial requirement FDA will need to enforce post-approval.

Codifying negotiation into the CFR means the program's mechanics survive a change in administration, not just an executive term, and the rule's proposed treatment of fixed-combination drugs, which iFeed flagged as unresolved in prior weeks, is now written down for comment. Irish and EU teams with combination products on the Medicare formulary should read that section specifically before 17 August.

42 CFR Part 429 (proposed); Medicare Drug Price Negotiation Program under Sections 1191-1198 of the Social Security Act, as required by the Inflation Reduction Act of 2022.

SaMD teams building radiology AI without a PCCP-based change-control process are now working against a codified special control, not just an FDA preference, algorithm retraining, threshold changes, and dataset expansion all need PCCP documentation before deployment under this classification.

21 CFR classification (91 FR 36522, Doc. 2026-12166); manufacturers of ML-based radiology quantitative imaging software fall under this Class II special-controls framework, including the PCCP documentation requirement, design verification/validation, and version-history labeling.

HPRA will relay the DHPC to Irish prescribers, and travel medicine practitioners need to apply the high-risk restriction now, before the label text itself is updated, since PRAC's guidance is that Ixchiq "should only be given to individuals 12 years of age and older who are at high risk of acquiring chikungunya infection and after careful consideration."

EMA PRAC benefit-risk review under GVP Module IX; DHPC dissemination to prescribers; the label itself has not yet caught up, so the DHPC is the operative document until it does.

MSSA bacteremia is common and carries meaningful mortality risk, so a trial-backed case for a lower-toxicity first-line agent is the sort of result Irish hospital empirical-prescribing guidelines tend to adopt within a cycle or two, not something that sits in the literature unused.

Peer-reviewed RCT evidence (NEJM, SNAP trial); hospital antimicrobial stewardship committees and formulary bodies are the relevant governance layer for adopting the finding into treatment protocols.

NICE decisions in SCLC get watched as comparator benchmarks well outside England, and NCPE and other EU HTA teams will inherit the same indirect-comparison uncertainty NICE's committee flagged when they model this indication.

NICE technology appraisal TA1167; NHS bodies in England and Wales have a statutory duty to fund and resource the recommended treatment once published.

Ruxolitinib for myelofibrosis has a narrow therapeutic margin, and WHO's own warning is blunt: use of a falsified product "may lead to treatment failure, resulting in progression of serious disease and an increased risk of death due to lack of therapeutic effect." HPRA and other national regulators will relay this alert to prescribers and pharmacies directly.

WHO substandard and falsified medical products surveillance; national pharmacovigilance and supply-chain controls

Irish oncology market-access teams tracking NCPE now have a concrete timeline to work against: submission received 9 June, preliminary review out 16 July, with the full assessment still to come, plan evidence and pricing strategy around that clock, not a general expectation of review.

NCPE HTA pathway (rapid review to full HTA escalation); HSE reimbursement decision follows the completed assessment.

Global pharma with Indian manufacturing or export exposure in dermatology, pain, antispasmodic, or antibiotic FDCs should check whether their portfolio includes a chemically similar combination, this is a standing India Watch category for iFeed, and DTAB's committee-review approach here is the template it's likely to keep using.

Drugs and Cosmetics Act (Section 26A); DTAB expert-committee clinical review preceding the MoHFW prohibitory order.